Evolocumab for coronary disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Coronary Artery Disease

Why this status

  1. 13 Mar 2019: Trial registered, NCT03872401
  2. 11 Jun 2019: Trial started, NCT03872401

The trials

NCT03872401: Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

State
Completed
Phase
Phase 3
People
12,301 taking part
Started
11 Jun 2019
Primary completion
25 Jul 2025
Arms
Evolocumab 140 mg Q2W
Results
Posted on the registry
  1. 13 Mar 2019: Trial registered
  2. 11 Jun 2019: Trial started
  3. 25 Jul 2025: Trial completed
  4. 25 Jun 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Evolocumab 140 MG/ML [Repatha], Repatha.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.